March 2021 – Fifth Eye

Posted March 9, 2021

FDA grants De Novo classification for innovative analytic technology developed at MCIRCC

Source: MCIRCC Michigan Medicine spin-off company, Fifth Eye, is launching their first product, the Analytic for Hemodynamic Instability (AHI). Read the full article >

FDA grants De Novo classification to Fifth Eye’s continuous hemodynamic status monitoring tool

Source: MobiHealthNews The Analytic for Hemodynamic Instability tool can identify hemodynamic instability with 96% sensitivity and detects stable patients with 85% specificity. Read the full [...]

FDA Grants De Novo to ML-based, Real-time Indicator of Patient Deterioration

Source: Fifth Eye Inc. Fifth Eye’s noninvasive tool is the first to provide continuous monitoring of hemodynamic status using a single ECG lead Read the full press release >